Digital Marketing Trends in Non-small Cell Lung Cancer
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Digital Marketing Trends in Non-small Cell Cancer Report Overview
Merck’s Keytruda.com achieved the highest total traffic across Non-small Cell Lung Cancer (NSCLC) patient sites in the US from October 2022 to September 2023. This was followed by BMS’s Opdivo.com and AstraZeneca’s Imfinzi.com. Keytruda.com was also supported by the most paid search engine optimization (SEO) at over 7,600 keywords, closely followed by Enhertu.com and Opdivo.com. Overall, the highest proportion of traffic to top branded patient NSCLC websites originated from direct and organic sources.
The Digital Marketing Trends in the Non-small Cell Cancer research report assesses key digital marketing metrics of pharma assets in CRC, including branded websites for patients and healthcare professionals (HCPs), mobile apps, and social media accounts. The report offers metrics on website traffic volume, engagement, source, digital display advertising (DDA), paid search engine optimization (SEO), and social media post interaction.
Key US Patient-Branded Websites | · Keytruda.com
· Opdivo.com · Imfinzi.com · Enhertu.com · Avastin.com · Libtayo.com |
Key US HCP Branded Websites | · Keytrudahcp.com
· Imfinzihcp.com · Lumakrashcp.com · Libtayohcp.com · Tagrissohcp.com · Enhertuhcp.com |
Key EUCAN Unbranded Websites | · Daskwort.de
· Pactonco.fr |
Enquire & Decide | Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase. |
Major US Patient Branded Websites for Non-small Cell Cancer
The major US patient-branded websites for Non-small Cell Cancer are Keytruda.com, Opdivo.com, Imfinzi.com, Enhertu.com, Avastin.com, and Libtayo.com. Merck’s Keytruda.com achieved the highest total traffic across NSCLC patient sites in the US from October 2022 to September 2023. This was followed by BMS’s Opdivo.com and AstraZeneca’s Imfinzi.com.
Traffic Share to Branded US CRC Patient Sites, October 2022 – September 2023 (%)
Buy the Full Report for More into Total Traffic Share Insights of the US Patient-Branded Websites Download a Free Report Sample
Major US HCP Branded Websites for Non-small Cell Cancer
The major US HCP-branded websites for Non-small Cell Cancer are Keytrudahcp.com, Imfinzihcp.com, Lumakrashcp.com, Libtayohcp.com, Tagrissohcp.com, and Enhertuhcp.com. AstraZeneca’s Imfinzihcp.com achieved the highest total traffic across NSCLC HCP sites in the US from October 2022 to September 2023. This was followed by Merck’s Keytrudahcp.com.
Traffic Share to Branded US CRC HCP Sites, October 2022 – September 2023 (%)
Buy the Full Report for More Insights into The Total Traffic Share of The US HCP Branded Websites
Major EUCAN Unbranded Websites for Non-small Cell Cancer
Roche’s Daskwort.de achieved the highest total traffic across NSCLC unbranded sites in EUCAN from October 2022 to September 2023. It was followed by Pfizer’s Pactonco.fr. Overall, the highest proportion of traffic to branded NSCLC websites for unbranded websites originated from organic sources, followed by direct.
Buy the Full Report for More Insights into The Total Traffic Share of the EUCAN-Unbranded Websites
Scope
- This report assesses key digital marketing metrics of pharma assets in NSCLC, including branded websites for patients and HCPs, Unbranded websites, and social media accounts.
- Metrics include website traffic volume, engagement, source, DDA, paid SEO, and social media post interaction.
- Countries include the US, 4EU (Italy, France, Germany, and Spain), the UK, and Canada (EUCAN).
Reasons to Buy
- Understand the digital marketing competitive landscape in NSCLC, with a view to leading patient and HCP branded assets across different regions.
- See what tactics pharma companies are using to drive traffic to their NSCLC branded assets for patients and HCPs, such as DDA and paid SEO.
- Understand what sources of website traffic are generating the most visits to these assets, such as paid SEO, social media, or organic searches.
- Compare top branded and unbranded assets for patients by how they address and support different patient needs.
- See what pharma social media accounts in PsO are the most active and achieving the most engagement.
BMS
AstraZeneca
Pfizer
Regeneron
Roche
Table of Contents
Frequently asked questions
-
Which is the leading US patient-branded website for Non-small Cell Cancer?
Keytruda.com is the leading US patient-branded website for Non-small Cell Cancer.
-
Which source has the highest proportion of traffic to top branded patient NSCLC websites?
The highest proportion of traffic to top branded patient NSCLC websites originated from direct and organic sources.
-
Which is the leading US HCP-branded website for Non-small Cell Cancer?
AstraZeneca’s Imfinzihcp.com is the leading US HCP-branded website for Non-small Cell Cancer.
-
Which website achieved the highest total traffic across NSCLC unbranded sites in EUCAN from October 2022 to September 2023?
Roche’s Daskwort.de achieved the highest total traffic across NSCLC unbranded sites in EUCAN from October 2022 to September 2023.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.